Artificial Intelligence to Measure Adherence to Oral Medication
Launched by NORTHWELL HEALTH · Aug 5, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how an artificial intelligence (AI) smartphone app can help people with first episode psychosis remember to take their oral medication regularly. The goal is to see if this technology can make it easier for patients to stick to their treatment plan, which is important for their recovery and overall health.
To be eligible for the trial, participants need to be enrolled in a specific program called a Coordinated Specialty Care (CSC) program and must be prescribed an oral antipsychotic medication. There are no specific exclusions for this trial, so most individuals meeting the criteria can participate. If you join the trial, you can expect to use the AI app, which will help track your medication use and provide reminders to take your medicine. This innovative approach aims to improve treatment adherence and support better outcomes for those experiencing their first episode of psychosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Enrolled in a CSC program
- • Prescribed an oral antipsychotic
- Exclusion Criteria:
- • none
About Northwell Health
Northwell Health is a leading integrated health system based in New York, dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to improving patient outcomes and enhancing medical knowledge, Northwell Health conducts a diverse range of clinical studies across various therapeutic areas. The organization harnesses its extensive network of hospitals, outpatient facilities, and research institutes to facilitate cutting-edge research, ensuring access to advanced treatments for patients while fostering collaboration among healthcare professionals, researchers, and industry partners. By prioritizing patient-centric approaches and leveraging state-of-the-art technology, Northwell Health aims to drive significant advancements in medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kalamazoo, Michigan, United States
Grand Rapids, Michigan, United States
Hialeah, Florida, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials